Telesis Bio to Present at RNA Leaders Europe Congress
Showcasing Benchtop Automation for mRNA Synthesis beginning from Sequence or Plasmid DNA
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their benchtop automation solutions for mRNA synthesis at RNA Leaders Europe Congress which begins tomorrow in Basel, Switzerland. In addition to exhibition, Telesis Bio will present in two sessions; Jyotsna Venugopal, Ph.D., Director of Product Marketing, will present “Automated synthetic biology solutions for optimizing CAR-T development workflows” in the opening day session, and Qi Zhang, Ph.D., Scientist, will present “Automated solutions for addressing mRNA synthesis bottlenecks in therapeutics discovery” in the poster session.
The award winning BioXp® system and associated BioXp® mRNA synthesis kits enables on-demand and automated synthesis of mRNA beginning from a customer’s sequence or own plasmid DNA, overnight and at the push of a button. The system enables researchers to optimize their discovery workflows by acquiring their mRNA of interest in days, rather than weeks or months.
“By enabling researchers to overcome the bottleneck created by long lead times to build or buy their mRNA, they can more tightly integrate and more quickly execute their design-build-test workflows. We believe our BioXp® system can empower researchers to accelerate drug discovery, particularly in the areas of oncological and infectious disease vaccine discovery,” said Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio.
For more information on the BioXp® mRNA Synthesis Kits or to place an order, please visit telesisbio.com/products/bioxp-kits/mrna-synthesis/.
About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio’s future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 11, 2022. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.
Vice President of Investor Relations
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
NORBIT - NOK 270 million frame agreement received for On-Board Units31.3.2023 11:45:00 CEST | Press release
Trondheim, 31 March 2023: Today, NORBIT is pleased to announce the award of a new frame agreement for delivery of On-Board Units from an undisclosed customer. The frame agreement covers deliveries for a two-year period across 2023-2025. The contract value is estimated to be in excess NOK 270 million. “Being able to conclude this significant frame agreement confirms that our strategy of migrating our On-Board Unit business into long term partnerships remains successful. This enables us to tailor our offering and bring added value to our customers”, says Per Jørgen Weisethaunet, CEO of NORBIT. For further queries, please contact: Per Jørgen Weisethaunet, CEO, +47 959 62 915 Per Kristian Reppe, CFO, +47 900 33 203 About NORBIT ASA NORBIT is a global company providing tailored technology to selected applications by solving challenges through innovative solutions, in line with its mission to Explore More. The company is structured in three business segments to address its key markets: Ocean
Ny afdeling Balance C Akkumulerende i Investeringsforeningen PFA Invest31.3.2023 11:27:08 CEST | Press release
Investeringsforeningen PFA Invests bestyrelse har den 8. marts 2023 besluttet at oprette af en ny afdeling, Balance C Akkumulerende. Afdelingen blev godkendt af Finanstilsynet den 10. januar 2023. Vedlagt offentliggøres tegningsprospektet for afdelingen under Investeringsforeningen PFA Invest • Balance C Akkumulerende Andele i afdelingen udbydes til tegning fra den 11. april 2023 til den 24. april 2023, begge dage inklusive, og andele udbydes i tegningsperioden til tegningskurs 100,20. Tegning af min. 1 mio. kr. i afdelingen er garanteret af PFA Pension, forsikringsaktieselskab. Resultat af tegningen forventes offentliggjort den 25. april 2023. NASDAQ OMX Copenhagen A/S har godkendt at andelene optages til handel med forventet 1. handelsdag den 28. april 2023. Yderligere information kan findes på www.pfainvest.dk Med venlig hilsen PFA Asset Management A/S Attachment Tegningsprospekt PFA Invest - Balance C Akkumulerende
Indkaldelse til ordinær generalforsamling i EAC Invest A/S - Selskabsmeddelelse nr. 2/202331.3.2023 10:58:37 CEST | pressemeddelelse
København, 31. marts 2023 Den ordinære generalforsamling i EAC Invest A/S vil blive afholdt fredag den 28. april 2023 kl. 11:00 i Asia House, Indiakaj 16, 2100 København Ø. Vedhæftet dagsorden med bilag. Med venlig hilsen, for EAC Invest A/S Bestyrelsen For yderligere information Kresten M. Valdal, CEO,Telefon: +45 82334044, e-mail firstname.lastname@example.org Vedhæftede filer EAC Invest AS - AGM 2023 IndkaldelseEAC Invest AS - AGM 2023 - Bilag 1 - Bestyrelseskandidater2023.02 Indkaldelse til ordinær generalforsamling i EAC Invest AS
Decisions of Innofactor Plc’s Annual General Meeting and the organizing meeting of the Board of Directors31.3.2023 10:20:00 CEST | Press release
Innofactor Plc Stock Exchange Release March 31, 2023, at 11.20 Finnish time Adopting the accounts and the group's financial statement and granting the members of the Board of Directors and the Chief Executive Officer discharge from liability The Annual General Meeting (AGM) of Innofactor Plc held on March 31, 2023, resolved to adopt the accounts and the group's financial statement for the financial period that ended on December 31, 2022, and granted the members of the Board of Directors and the Chief Executive Officer discharge from liability for the financial period that ended on December 31, 2022. Deciding on the use of the profit shown on the balance sheet and the payment of dividend The AGM decided, in accordance with the proposal of the Board of Directors, that no dividend will be paid for the financial period of 2022. The AGM decided on a repayment of capital of EUR 0,06 per share to be paid. The repayment of capital shall be paid to shareholders who on the record date of the cap
AFARAK GROUP SE'S PUBLISHES FINANCIAL STATEMENTS 202231.3.2023 10:18:29 CEST | Press release
09:15 London, 11:15 Helsinki, 31 March 2023 - Afarak Group SE ("Afarak" or "the Company") (LSE: AFRK, OMX: AFAGR) Annual Financial Report AFARAK GROUP SE'S PUBLISHES FINANCIAL STATEMENTS 2022 Afarak Group announces that it has published today its Board of directors report, Financial Statement for the year 2022, the Auditor’s Report and the Corporate Governance Statement which is available from the Company's website www.afarak.com. Afarak publishes the Financial Statements in accordance with European Single Electronic Format (ESEF) reporting requirements with the XHTML format labelled with XBRL tags, which are available as zip file attached to this release. A copy of the Board of Directors report and the Financial Statements for the year 2022 has been submitted to the UK's National Storage Mechanism. Afarak will hold its 2023 Annual General Meeting in Helsinki on within the time stipulated in the Finnish Companies Act. Helsinki 31 March 2023 Guy Konsbruck CEO For additional information,